Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)

Basit Öğe Kaydı
dc.authoridSposetti, Caterina/0000-0003-3211-8516
dc.contributor.authorAndre, Thierry
dc.contributor.authorSposetti, Caterina
dc.contributor.authorGümüş, Mahmut
dc.contributor.authorAhn, Joong Bae
dc.contributor.authorWyrwicz, Lucjan
dc.contributor.authorKwiatkowski, Mariusz
dc.contributor.authorKim, Jong Gwang
dc.date.accessioned2025-05-10T19:27:40Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 03-07, 2022 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.description.sponsorshipAmer Soc Clin Oncol
dc.description.sponsorshipMerck Sharp Dohme Corp.
dc.description.sponsorshipMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue16
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14730/7028
dc.identifier.volume40
dc.identifier.wosWOS:000863680304906
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titlePhase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu